It’s not every day that I get the opportunity to speak directly to current and potential future investors who are investing in a new device to treat not only brain cancer but, hopefully, other solid tumors as well. I was delighted when Chair and President, John Butters, asked me to speak last Monday in Seattle at Nativis’ annual shareholder’s meeting.
I am hopeful that I was able to “encourage” more investment not only into the Nativis Voyager System, www.Nativis.com, but also into other new and innovative bio-tech & bio-med treatments for brain tumors and brain cancer.
The Nativis Voyager System is now in feasibility clinical trials in Seattle, Austin and Long Island, ID #NCT02296580:
- Seattle: Swedish Neuroscience Institute/Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment. The Principal Investigator is Charles Cobbs, MD.
- Seton Brain & Spine Institute, TX. The Principal Investigator is Brian Vaillant, MD.
- Long Island Brain Tumor Center at Neurological Surgery P.C. The Principal Investigator at this site is Paul Duic, MD.
For additional information on this trial, please reach out to Deborah Sheffield, MS, firstname.lastname@example.org to Info@ChrisElliottFund.org and/or Info@EndBrainCancer.org, 800-74-5703 10:30a – 3:00p PST.
While in DC last month, I had the opportunity to speak directly with Senator Maria Cantwell regarding the NovoTTF device, now known as the Optune Device. I wanted to encourage Senator Cantwell to help the Chris Elliott Fund and the EndBrainCancer Collaberative to remove the barriers that these companies face while practicing “Best Practices” designated by the FDA. I also noted the need for a new CMS code as currently, these devices are actually classified as “Durable Medical Devices” (DME), much the same as a wheel chair, when in fact, these devices should be classified in a similar manner to drug/chemo treatment for cancer or at the very least, they should have a new classification code.
I look forward to keeping you posted on our Advocacy efforts in DC, on all innovative therapy ad devices to fight brain cancer as well as keeping you updated on the Nativis Voyager System. Personally, I get goose bumps each time a new therapy and/or device becomes available for brain tumor patients. The Chris Elliott Fund, www.ChrisElliottFund.org and/or www.EndBrainCancer.org will continue to fight for each patient’s right to IMMEDIATE ACCESS and EXPANDED ACCESS.
Please feel free to reach out directly if you’d like more information, would like to support our efforts or would like to get in touch with the doctors involved in this research and this study.
Dellann Elliott Mydland
Founder & President
The Chris Elliott Fund